

*Treatment-Emergent Adverse Events by descending frequency -SOC continued
Safety Analysis Set*

System Organ Class Preferred Term	Placebo (N=86)		Low Dose (N=84)		High Dose (N=84)	
	n	(%)	n	(%)	n	(%)
Overall	65	(75.6%)	77	(91.7%)	76	(90.5%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	21	(24.4%)	47	(56.0%)	40	(47.6%)
APPLICATION SITE PRURITUS	6	(7.0%)	22	(26.2%)	22	(26.2%)
APPLICATION SITE ERYTHEMA	3	(3.5%)	12	(14.3%)	15	(17.9%)
APPLICATION SITE IRRITATION	3	(3.5%)	9	(10.7%)	9	(10.7%)
APPLICATION SITE DERMATITIS	5	(5.8%)	9	(10.7%)	7	(8.3%)
APPLICATION SITE VESICLES	1	(1.2%)	4	(4.8%)	6	(7.1%)
FATIGUE	1	(1.2%)	5	(6.0%)	5	(6.0%)
APPLICATION SITE PAIN	0		0		2	(2.4%)
APPLICATION SITE PERSPIRATION	0		0		2	(2.4%)
APPLICATION SITE SWELLING	0		1	(1.2%)	2	(2.4%)
CHEST DISCOMFORT	0		0		2	(2.4%)
CHEST PAIN	0		0		2	(2.4%)
MALAISE	0		1	(1.2%)	2	(2.4%)
OEDEMA PERIPHERAL	2	(2.3%)	1	(1.2%)	2	(2.4%)
APPLICATION SITE DISCHARGE	0		0		1	(1.2%)
APPLICATION SITE REACTION	1	(1.2%)	0		1	(1.2%)
APPLICATION SITE URTICARIA	0		2	(2.4%)	1	(1.2%)
ASTHENIA	1	(1.2%)	0		1	(1.2%)
CHILLS	1	(1.2%)	1	(1.2%)	1	(1.2%)
FEELING ABNORMAL	0		0		1	(1.2%)
FEELING COLD	0		0		1	(1.2%)
PAIN	0		1	(1.2%)	1	(1.2%)
PYREXIA	2	(2.3%)	0		1	(1.2%)
APPLICATION SITE BLEEDING	0		1	(1.2%)	0	

*Treatment-Emergent Adverse Events by descending frequency -SOC continued
Safety Analysis Set*

System Organ Class Preferred Term	Placebo (N=86)		Low Dose (N=84)		High Dose (N=84)	
	n	(%)	n	(%)	n	(%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS						
APPLICATION SITE DESQUAMATION	0		1 (1.2%)		0	
APPLICATION SITE DISCOLOURATION	0		1 (1.2%)		0	
APPLICATION SITE INDURATION	1 (1.2%)		0		0	
APPLICATION SITE WARMTH	0		1 (1.2%)		0	
INFLAMMATION	0		1 (1.2%)		0	
OEDEMA	0		2 (2.4%)		0	
SECRETION DISCHARGE	0		1 (1.2%)		0	
SUDDEN DEATH	0		1 (1.2%)		0	
SWELLING	0		1 (1.2%)		0	
ULCER	0		1 (1.2%)		0	
SKIN AND SUBCUTANEOUS TISSUE DISORDERS						
	20 (23.3%)		39 (46.4%)		40 (47.6%)	
PRURITUS	8 (9.3%)		21 (25.0%)		26 (31.0%)	
ERYTHEMA	8 (9.3%)		14 (16.7%)		14 (16.7%)	
RASH	5 (5.8%)		13 (15.5%)		9 (10.7%)	
HYPERHIDROSIS	2 (2.3%)		4 (4.8%)		8 (9.5%)	
SKIN IRRITATION	3 (3.5%)		6 (7.1%)		5 (6.0%)	
RASH PRURITIC	0		1 (1.2%)		2 (2.4%)	
ACTINIC KERATOSIS	0		0		1 (1.2%)	
BLISTER	0		5 (6.0%)		1 (1.2%)	
PRURITUS GENERALISED	0		1 (1.2%)		1 (1.2%)	
RASH MACULO-PAPULAR	0		0		1 (1.2%)	
SKIN ODOUR ABNORMAL	0		0		1 (1.2%)	
URTICARIA	0		1 (1.2%)		1 (1.2%)	
ALOPECIA	1 (1.2%)		0		0	
COLD SWEAT	1 (1.2%)		0		0	

*Treatment-Emergent Adverse Events by descending frequency -SOC continued
Safety Analysis Set*

System Organ Class Preferred Term	Placebo (N=86)		Low Dose (N=84)		High Dose (N=84)	
	n	(%)	n	(%)	n	(%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS						
DERMATITIS CONTACT	0		1 (1.2%)		0	
DRUG ERUPTION	1 (1.2%)		0		0	
RASH ERYTHEMATOUS	0		1 (1.2%)		0	
SKIN EXFOLIATION	0		1 (1.2%)		0	
SKIN ULCER	1 (1.2%)		0		0	
NERVOUS SYSTEM DISORDERS	8 (9.3%)		20 (23.8%)		25 (29.8%)	
DIZZINESS	2 (2.3%)		8 (9.5%)		11 (13.1%)	
HEADACHE	3 (3.5%)		3 (3.6%)		5 (6.0%)	
SYNCOPE	0		4 (4.8%)		3 (3.6%)	
BURNING SENSATION	0		0		2 (2.4%)	
AMNESIA	0		0		1 (1.2%)	
COGNITIVE DISORDER	0		0		1 (1.2%)	
HYPERSONMIA	0		0		1 (1.2%)	
LETHARGY	0		1 (1.2%)		1 (1.2%)	
PARAESTHESIA	0		0		1 (1.2%)	
PAROSMIA	0		0		1 (1.2%)	
PARTIAL SEIZURES WITH SECONDARY GENERALISATION	0		0		1 (1.2%)	
SOMNOLENCE	2 (2.3%)		3 (3.6%)		1 (1.2%)	
SYNCOPE VASOVAGAL	0		0		1 (1.2%)	
TRANSIENT ISCHAEMIC ATTACK	0		2 (2.4%)		1 (1.2%)	
BALANCE DISORDER	0		1 (1.2%)		0	
COMPLEX PARTIAL SEIZURES	0		1 (1.2%)		0	
COORDINATION ABNORMAL	0		1 (1.2%)		0	
HEMIANOPIA HOMONYMOUS	0		1 (1.2%)		0	
PARAESTHESIA ORAL	0		1 (1.2%)		0	

*Treatment-Emergent Adverse Events by descending frequency -SOC continued
Safety Analysis Set*

System Organ Class Preferred Term	Placebo (N=86)		Low Dose (N=84)		High Dose (N=84)	
	n	(%)	n	(%)	n	(%)
NERVOUS SYSTEM DISORDERS						
PARKINSON'S DISEASE	1	(1.2%)	0		0	
PSYCHOMOTOR HYPERACTIVITY	1	(1.2%)	0		0	
STUPOR	0		1	(1.2%)	0	
GASTROINTESTINAL DISORDERS	17	(19.8%)	14	(16.7%)	20	(23.8%)
VOMITING	3	(3.5%)	3	(3.6%)	7	(8.3%)
NAUSEA	3	(3.5%)	3	(3.6%)	6	(7.1%)
DIARRHOEA	9	(10.5%)	4	(4.8%)	4	(4.8%)
SALIVARY HYPERSECRETION	0		0		4	(4.8%)
ABDOMINAL DISCOMFORT	0		0		1	(1.2%)
ABDOMINAL PAIN	1	(1.2%)	3	(3.6%)	1	(1.2%)
GASTROINTESTINAL HAEMORRHAGE	0		0		1	(1.2%)
STOMACH DISCOMFORT	0		0		1	(1.2%)
CONSTIPATION	1	(1.2%)	0		0	
DYSPEPSIA	1	(1.2%)	1	(1.2%)	0	
DYSPHAGIA	0		1	(1.2%)	0	
FLATULENCE	1	(1.2%)	0		0	
GASTROESOPHAGEAL REFLUX DISEASE	1	(1.2%)	0		0	
GLOSSITIS	1	(1.2%)	0		0	
HIATUS HERNIA	1	(1.2%)	0		0	
RECTAL HAEMORRHAGE	0		1	(1.2%)	0	
CARDIAC DISORDERS	12	(14.0%)	13	(15.5%)	15	(17.9%)
SINUS BRADYCARDIA	2	(2.3%)	7	(8.3%)	8	(9.5%)
MYOCARDIAL INFARCTION	4	(4.7%)	2	(2.4%)	4	(4.8%)
ATRIAL FIBRILLATION	1	(1.2%)	1	(1.2%)	3	(3.6%)
ATRIAL FLUTTER	0		1	(1.2%)	1	(1.2%)

*Treatment-Emergent Adverse Events by descending frequency -SOC continued
Safety Analysis Set*

System Organ Class Preferred Term	Placebo (N=86)	Low Dose (N=84)	High Dose (N=84)
	n (%)	n (%)	n (%)
CARDIAC DISORDERS			
CARDIAC DISORDER	0	0	1 (1.2%)
SUPRAVENTRICULAR EXTRASYSTOLES	1 (1.2%)	1 (1.2%)	1 (1.2%)
VENTRICULAR EXTRASYSTOLES	0	2 (2.4%)	1 (1.2%)
ATRIAL HYPERTROPHY	1 (1.2%)	0	0
ATRIOVENTRICULAR BLOCK FIRST DEGREE	1 (1.2%)	1 (1.2%)	0
ATRIOVENTRICULAR BLOCK SECOND DEGREE	1 (1.2%)	0	0
BRADYCARDIA	1 (1.2%)	0	0
BUNDLE BRANCH BLOCK LEFT	1 (1.2%)	0	0
BUNDLE BRANCH BLOCK RIGHT	1 (1.2%)	1 (1.2%)	0
CARDIAC FAILURE CONGESTIVE	1 (1.2%)	0	0
PALPITATIONS	0	2 (2.4%)	0
SINUS ARRHYTHMIA	1 (1.2%)	0	0
SUPRAVENTRICULAR TACHYCARDIA	0	1 (1.2%)	0
TACHYCARDIA	1 (1.2%)	0	0
VENTRICULAR HYPERTROPHY	1 (1.2%)	0	0
WOLFF-PARKINSON-WHITE SYNDROME	0	1 (1.2%)	0
INFECTIONS AND INFESTATIONS	16 (18.6%)	9 (10.7%)	13 (15.5%)
NASOPHARYNGITIS	2 (2.3%)	4 (4.8%)	6 (7.1%)
UPPER RESPIRATORY TRACT INFECTION	6 (7.0%)	1 (1.2%)	3 (3.6%)
CYSTITIS	1 (1.2%)	0	1 (1.2%)
HORDEOLUM	0	0	1 (1.2%)
INFLUENZA	1 (1.2%)	1 (1.2%)	1 (1.2%)
LOWER RESPIRATORY TRACT INFECTION	0	0	1 (1.2%)
RHINITIS	0	0	1 (1.2%)
URINARY TRACT INFECTION	2 (2.3%)	0	1 (1.2%)

*Treatment-Emergent Adverse Events by descending frequency -SOC continued
Safety Analysis Set*

System Organ Class Preferred Term	Placebo (N=86)		Low Dose (N=84)		High Dose (N=84)	
	n	(%)	n	(%)	n	(%)
INFECTIONS AND INFESTATIONS						
BRONCHITIS	1	(1.2%)	0		0	
CELLULITIS	0		1	(1.2%)	0	
CERVICITIS	1	(1.2%)	0		0	
EAR INFECTION	2	(2.3%)	0		0	
GASTROENTERITIS VIRAL	1	(1.2%)	0		0	
LOCALISED INFECTION	1	(1.2%)	0		0	
PNEUMONIA	0		1	(1.2%)	0	
VAGINAL MYCOSIS	1	(1.2%)	0		0	
VIRAL INFECTION	0		1	(1.2%)	0	
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	8	(9.3%)	9	(10.7%)	10	(11.9%)
COUGH	1	(1.2%)	5	(6.0%)	5	(6.0%)
NASAL CONGESTION	3	(3.5%)	1	(1.2%)	3	(3.6%)
EPISTAXIS	0		1	(1.2%)	2	(2.4%)
ALLERGIC GRANULOMATOUS ANGIITIS	0		0		1	(1.2%)
DYSPNOEA	1	(1.2%)	1	(1.2%)	1	(1.2%)
PHARYNGEAL ERYTHEMA	0		0		1	(1.2%)
PHARYNGOLARYNGEAL PAIN	0		1	(1.2%)	1	(1.2%)
PRODUCTIVE COUGH	0		0		1	(1.2%)
RESPIRATORY TRACT CONGESTION	0		0		1	(1.2%)
RHINORRHOEA	0		1	(1.2%)	1	(1.2%)
DYSPHONIA	0		1	(1.2%)	0	
EMPHYSEMA	1	(1.2%)	0		0	
HAEMOPTYSIS	1	(1.2%)	0		0	
POSTNASAL DRIP	1	(1.2%)	0		0	
RALES	1	(1.2%)	0		0	

*Treatment-Emergent Adverse Events by descending frequency -SOC continued
Safety Analysis Set*

System Organ Class Preferred Term	Placebo (N=86)		Low Dose (N=84)		High Dose (N=84)	
	n	(%)	n	(%)	n	(%)
PSYCHIATRIC DISORDERS	10	(11.6%)	10	(11.9%)	8	(9.5%)
INSOMNIA	2	(2.3%)	0		2	(2.4%)
AGITATION	2	(2.3%)	2	(2.4%)	1	(1.2%)
CONFUSIONAL STATE	2	(2.3%)	3	(3.6%)	1	(1.2%)
DELIRIUM	0		0		1	(1.2%)
DELUSION	1	(1.2%)	0		1	(1.2%)
HALLUCINATION	0		0		1	(1.2%)
HALLUCINATION, VISUAL	0		0		1	(1.2%)
LIBIDO DECREASED	0		0		1	(1.2%)
LISTLESS	0		0		1	(1.2%)
NIGHTMARE	0		0		1	(1.2%)
ANXIETY	0		3	(3.6%)	0	
COMPLETED SUICIDE	1	(1.2%)	0		0	
DEPRESSED MOOD	0		1	(1.2%)	0	
DISORIENTATION	1	(1.2%)	0		0	
IRRITABILITY	1	(1.2%)	1	(1.2%)	0	
RESTLESSNESS	0		1	(1.2%)	0	
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	4	(4.7%)	7	(8.3%)	7	(8.3%)
BACK PAIN	1	(1.2%)	1	(1.2%)	3	(3.6%)
ARTHRALGIA	1	(1.2%)	2	(2.4%)	1	(1.2%)
ARTHRITIS	0		0		1	(1.2%)
FLANK PAIN	0		0		1	(1.2%)
MUSCLE SPASMS	0		1	(1.2%)	1	(1.2%)
MYALGIA	0		0		1	(1.2%)
MUSCULAR WEAKNESS	0		1	(1.2%)	0	

*Treatment-Emergent Adverse Events by descending frequency -SOC continued
Safety Analysis Set*

System Organ Class Preferred Term	Placebo (N=86)	Low Dose (N=84)	High Dose (N=84)
	n (%)	n (%)	n (%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS			
PAIN IN EXTREMITY	1 (1.2%)	0	0
SHOULDER PAIN	1 (1.2%)	2 (2.4%)	0
INVESTIGATIONS	10 (11.6%)	6 (7.1%)	6 (7.1%)
BIOPSY	0	0	1 (1.2%)
BIOPSY PROSTATE	0	0	1 (1.2%)
BLOOD CHOLESTEROL INCREASED	0	0	1 (1.2%)
BLOOD GLUCOSE INCREASED	0	1 (1.2%)	1 (1.2%)
ELECTROCARDIOGRAM T WAVE INVERSION	2 (2.3%)	1 (1.2%)	1 (1.2%)
WEIGHT DECREASED	0	0	1 (1.2%)
BLOOD ALKALINE PHOSPHATASE INCREASED	1 (1.2%)	0	0
BLOOD CREATINE PHOSPHOKINASE INCREASED	1 (1.2%)	0	0
BLOOD URINE PRESENT	1 (1.2%)	0	0
BODY TEMPERATURE INCREASED	0	1 (1.2%)	0
CYSTOSCOPY	1 (1.2%)	0	0
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	4 (4.7%)	1 (1.2%)	0
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED	1 (1.2%)	1 (1.2%)	0
HEART RATE INCREASED	1 (1.2%)	0	0
HEART RATE IRREGULAR	1 (1.2%)	0	0
NASAL MUCOSA BIOPSY	0	1 (1.2%)	0
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	4 (4.7%)	5 (6.0%)	5 (6.0%)
CONTUSION	1 (1.2%)	1 (1.2%)	2 (2.4%)
HIP FRACTURE	1 (1.2%)	0	2 (2.4%)
EXCORIATION	2 (2.3%)	1 (1.2%)	1 (1.2%)
FACIAL BONES FRACTURE	0	0	1 (1.2%)
FALL	1 (1.2%)	2 (2.4%)	1 (1.2%)

*Treatment-Emergent Adverse Events by descending frequency -SOC continued
Safety Analysis Set*

System Organ Class Preferred Term	Placebo (N=86)		Low Dose (N=84)		High Dose (N=84)	
	n	(%)	n	(%)	n	(%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS						
JOINT DISLOCATION	0		1 (1.2%)		0	
SKIN LACERATION	1 (1.2%)		2 (2.4%)		0	
WOUND	0		1 (1.2%)		0	
RENAL AND URINARY DISORDERS	4 (4.7%)		3 (3.6%)		3 (3.6%)	
CALCULUS URETHRAL	0		0		1 (1.2%)	
MICTURITION URGENCY	1 (1.2%)		1 (1.2%)		1 (1.2%)	
NEPHROLITHIASIS	1 (1.2%)		0		1 (1.2%)	
DYSURIA	1 (1.2%)		1 (1.2%)		0	
INCONTINENCE	0		1 (1.2%)		0	
POLLAKIURIA	1 (1.2%)		0		0	
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	0		1 (1.2%)		2 (2.4%)	
VENTRICULAR SEPTAL DEFECT	0		1 (1.2%)		2 (2.4%)	
METABOLISM AND NUTRITION DISORDERS	6 (7.0%)		1 (1.2%)		2 (2.4%)	
DECREASED APPETITE	1 (1.2%)		0		1 (1.2%)	
INCREASED APPETITE	1 (1.2%)		0		1 (1.2%)	
DEHYDRATION	1 (1.2%)		0		0	
DIABETES MELLITUS	1 (1.2%)		0		0	
FOOD CRAVING	1 (1.2%)		1 (1.2%)		0	
HYPONATRAEMIA	1 (1.2%)		0		0	
SURGICAL AND MEDICAL PROCEDURES	2 (2.3%)		1 (1.2%)		2 (2.4%)	
ACROCHORDON EXCISION	0		0		1 (1.2%)	
SKIN LESION EXCISION	0		0		1 (1.2%)	
CATARACT OPERATION	1 (1.2%)		1 (1.2%)		0	
EYE LASER SURGERY	1 (1.2%)		0		0	
EAR AND LABYRINTH DISORDERS	1 (1.2%)		2 (2.4%)		1 (1.2%)	

*Treatment-Emergent Adverse Events by descending frequency -SOC continued
Safety Analysis Set*

System Organ Class Preferred Term	Placebo (N=86)		Low Dose (N=84)		High Dose (N=84)	
	n	(%)	n	(%)	n	(%)
EAR AND LABYRINTH DISORDERS						
VERTIGO	0		1 (1.2%)		1 (1.2%)	
CERUMEN IMPACTION	0		1 (1.2%)		0	
EAR PAIN	1 (1.2%)		0		0	
EYE DISORDERS	2 (2.3%)		2 (2.4%)		1 (1.2%)	
VISION BLURRED	0		1 (1.2%)		1 (1.2%)	
CONJUNCTIVAL HAEMORRHAGE	0		1 (1.2%)		0	
CONJUNCTIVITIS	1 (1.2%)		0		0	
EYE ALLERGY	1 (1.2%)		0		0	
EYE PRURITUS	1 (1.2%)		0		0	
EYE SWELLING	1 (1.2%)		0		0	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	0		2 (2.4%)		1 (1.2%)	
PROSTATE CANCER	0		0		1 (1.2%)	
COLON CANCER	0		1 (1.2%)		0	
MALIGNANT FIBROUS HISTIOCYTOMA	0		1 (1.2%)		0	
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	2 (2.3%)		0		1 (1.2%)	
BENIGN PROSTATIC HYPERPLASIA	1 (1.2%)		0		1 (1.2%)	
PELVIC PAIN	1 (1.2%)		0		0	
SOCIAL CIRCUMSTANCES	0		0		1 (1.2%)	
ALCOHOL USE	0		0		1 (1.2%)	
VASCULAR DISORDERS	3 (3.5%)		3 (3.6%)		1 (1.2%)	
WOUND HAEMORRHAGE	0		0		1 (1.2%)	
HOT FLUSH	0		1 (1.2%)		0	
HYPERTENSION	1 (1.2%)		1 (1.2%)		0	
HYPOTENSION	2 (2.3%)		1 (1.2%)		0	
ORTHOSTATIC HYPOTENSION	1 (1.2%)		0		0	

Treatment-Emergent Adverse Events by descending frequency -SOC continued
Safety Analysis Set

System Organ Class Preferred Term	Placebo (N=86)		Low Dose (N=84)		High Dose (N=84)	
	n	(%)	n	(%)	n	(%)
HEPATOBIILIARY DISORDERS	1	(1.2%)	0		0	
HYPERBILIRUBINAEMIA	1	(1.2%)	0		0	
IMMUNE SYSTEM DISORDERS	0		1	(1.2%)	0	
HYPERSENSITIVITY	0		1	(1.2%)	0	